Journal of Antimicrobial Chemotherapy (1999) 44, 235-242
© 1999 The British Society for Antimicrobial Chemotherapy
Population pharmacokinetics of amikacin in patients with haematological malignancies
a Department of Pharmacy and Pharmaceutical Technology, University of Salamanca b Faculty of Chemical Sciences, University Aut.of San Luis Potosí, Mexico c Pharmacy Service, University Hospital of Salamanca d Department of Haematology, University Hospital of Salamanca, Salamanca, Spain
The aim of this study was to analyse the pharmacokinetic behaviour of amikacin in patients with haematological malignancies using a mixed-effect model and sparse data collected during routine clinical care. The patient population comprised 207 haematology patients divided into two groups: one for computing the population model (n= 134) and the other for validation (n = 73). A one-compartment model was used and the following covariates were tested for their influence on clearance and volume of distribution: age, gender, weight, parenteral nutrition, creatinine clearance, stage of antineoplastic treatment (induction, consolidation, intensification), number of weeks postchemotherapy, clinical diagnosis, Eastern Cooperative Oncology Group score, neutropenia, hypoalbuminaemia, concomitant medication (vancomycin and/or amphotericin B), overhydration, and autologous or allogenic bone marrow transplant. The nonlinear mixed-effect model (NONMEM) was used to assess the population pharmacokinetic model of amikacin in these patients. Apart from bodyweight and renal function, acute myeloblastic leukaemia and hypoalbuminaemia proved to be the most important covariates explaining the interindividual variability in amikacin pharmacokinetics in patients with haematological malignancies. The predictive performance of this population model for amikacin serum concentrations seems suitable for clinical purposes.
* Correspondence address. Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Avda. Campo Charro s/n, 37007 Salamanca, Spain. Tel: +349-23-294536; Fax: +349-23-294515; E-mail: jmlanao{at}gugu.usal.es
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
Y. Tanigawara, R. Sato, K. Morita, M. Kaku, N. Aikawa, and K. Shimizu Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3754 - 3762. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Buelga, M. del Mar Fernandez de Gatta, E. V. Herrera, A. Dominguez-Gil, and M. J. Garcia Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4934 - 4941. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Pea, P. Viale, D. Damiani, F. Pavan, F. Cristini, R. Fanin, and M. Furlanut Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3550 - 3553. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cavaliere, G. Conti, U. Moscato, F. Meo, M. A. Pennisi, R. Costa, and R. Proietti Hypoalbuminaemia does not impair Diprifusor performance during sedation with propofol Br. J. Anaesth., April 1, 2005; 94(4): 453 - 458. [Abstract] [Full Text] [PDF] |
||||

